Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Inclusion Criteria:

• Males or females aged ≥ 18 years

• Coronary artery disease with a clinically diagnosed peripheral neuropathy

• Willing and able to provide signed informed consent and Health Insurance Portabilityand Accountability Act (HIPAA) authorization

• Willing and able to comply with the requirements of the protocol and follow directionsfrom the clinic staff

Exclusion Criteria:

• History of allergy or intolerance to ranolazine

• Any condition or concomitant medication that would have precluded the safe use ofranolazine as outlined in the prescribing information sheet (see Appendix E)

• In the judgment of the investigator, any clinically-significant ongoing medicalcondition that might jeopardize the patient's safety or interfere with the absorption,distribution, metabolism or excretion of the study drug

• In the judgment of the investigator, clinically-significant abnormal physical findingsduring screening (excluding the patient's peripheral neuropathy condition)

• Use of any experimental or investigational drug or device within 30 days prior toscreening

• Pregnant or breast feeding, or (if premenopausal), not practicing an acceptable methodof birth control (as detailed in Inclusion Criterion 4)

• Had received prior treatment with, or investigational exposure to, ranolazine within 7days prior to randomization

• Clinically significant hepatic impairment

• Had end-stage renal disease requiring dialysis

• Psychological or addictive disorders (not limited to, but including drug and/oralcohol dependency) that may have precluded patient consent or compliance, or that mayhave confounded study interpretation

• Positive pregnancy test at Baseline (pre-randomization, Day 0)